
- /
- Supported exchanges
- / MU
- / ON4.MU
Ono Pharmaceutical Co. Ltd (ON4 MU) stock market data APIs
Ono Pharmaceutical Co. Ltd Financial Data Overview
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ono Pharmaceutical Co. Ltd data using free add-ons & libraries
Get Ono Pharmaceutical Co. Ltd Fundamental Data
Ono Pharmaceutical Co. Ltd Fundamental data includes:
- Net Revenue: 484 298 M
- EBITDA: 137 188 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-01-29
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ono Pharmaceutical Co. Ltd News

ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pha...


Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
By Rocky Swift TOKYO, April 30 (Reuters) - Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European mar...

Deciphera Catapults 73% On Ono Pharmaceutical's $2.4 Billion Takeover
Deciphera stock rocketed to a three-year high Monday after Ono Pharmaceutical agreed to buy it for $2.4 billion. Continue Reading View Comments

UPDATE 2-Japan's Ono to buy US drugmaker Deciphera for $2.4 bln
(Adds details on deal in paragraph 2) April 29 (Reuters) - Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drug developer for $2.4 billion in cash. Ono...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.